Objective From 1995, the European Association of Hospital Pharmacists (EAHP) has regularly investigated the progress of the hospital pharmacy profession in Europe, and identified key barriers and drivers of this. The most recent ‘Investigation of the Hospital Pharmacy Profession in Europe’ was conducted from November 2022 to March 2023. Methods The online questionnaire was sent to all hospital pharmacies in EAHP member countries. The investigation was drafted using the same questions as the 2015 baseline survey. Where possible and relevant, responses were compared with the data from previous surveys that monitored the implementation of the EAHP statements. Keele University, Centre for Medicines Optimisation, School of Pharmacy and Bioengineering, UK analysed the data. Results The overall number of responses was 653, with a better response rate of 19% compared with 14% in 2018 statements survey. The findings indicated that participating hospital pharmacies have similar characteristics to previous surveys. Section 1 (Introductory statements and governance), section 2 (Selection, procurement and distribution), section 3 (Production and compounding), section 5 (Patient safety and quality assurance) questions were generally answered positively, with results ranging from 52% to 90%. However, results for section 4 (Clinical pharmacy services) returned lower levels of positivity, with responses from 8 of the 15 questions being less than 60%. When asked what is preventing hospital pharmacists from achieving implementation of these activities, most answers were limited capacity, not considered to be a priority by managers, or other healthcare professionals do this. The last section focused on self-assessment and action planning, with fewer than 50% of positive responses; COVID-19 preparedness and vaccines with mixed positive and negative responses. Furthermore, implementation of the falsified medicines directive impacted the medication handling processes in 50% or more of the answers. Regarding sustainability, the majority (59%) of respondents felt a greater focus should be on sustainability from an organisational or management perspective. Conclusion Results offer valuable insights into the hospital pharmacy profession throughout Europe. While there have been improvements in certain areas, challenges remain, particularly in implementing clinical pharmacy services. The findings provide a foundation for further dialogue, advocacy, and strategic planning to advance the role of hospital pharmacists and enhance patient care in Europe’s healthcare systems.

Background: The accelerated development of novel cancer therapies necessitates a thorough understanding of the associated cardiotoxicity profiles, due to their significant implications for the long-term health and quality of life of cancer survivors. Objectives: The aim of this study was to determine the association between cardiotoxicity and non-small cell lung cancer (NSCLC) treatments using a hospital medicines usage database in England. Methods: An observational study based on a retrospective design using real-world data from the UK DEFINE database was performed. Monthly secondary data of 40 shortlisted drugs from April 2017 to July 2022 were extracted. Results: The cardiology drug that was associated with most oncology drugs was apixaban. Atezolizumab, bevacizumab, nintedanib, osimertinib, paclitaxel, pembrolizumab, gemcitabine and vincristine were all mostly associated with apixaban, which indicated association with atrial fibrillation. Afatinib, erlotinib and methotrexate were mostly associated with atenolol, hence suggesting the association with ischaemia or hypertension. Docetaxel and epirubicin were associated with verapamil, which indicated association with arrhythmia or hypertension. Conclusions: From the correlation and regression analyses, it can be concluded that hypertension was the most associated cardiovascular disease with the 20 shortlisted oncology drugs. The findings of this study have provided a better understanding of the association between each NSCLC–Cardio drug pair.

Prescribing errors are common, occurring in 7% of in-patient medication orders in UK hospitals. Foundation Year 1 (F1) doctors have reported a lack of feedback on prescribing as a cause of errors. To evaluate the effect of implementing a shared learning intervention to Foundation Year 1 doctors on their prescribing errors. A shared learning intervention, ‘good prescribing tip’ emails, were designed and sent fortnightly to F1s to share feedback about common/serious prescribing errors occurring in the hospital. Ward pharmacists identified prescribing errors in newly prescribed in-patient and discharge medication orders for 2 weeks pre- and post-intervention during Winter/Spring 2017. The prevalence of prescribing errors was compared pre- and post-intervention using statistical analysis. Overall, there was a statistically significant reduction (p < 0.05) in the prescribing error rate between pre-intervention (441 errors in 6190 prescriptions, 7.1%) and post-intervention (245 errors in 4866 prescriptions, 5.0%). When data were analysed by ward type there was a statistically significant reduction in the prescribing error rate on medical wards (6.8% to 4.5%) and on surgical wards (8.4% to 6.2%). It is possible to design and implement a shared learning intervention, the ‘good prescribing tip’ email. Findings suggest that this intervention contributed to a reduction in the prevalence of prescribing errors across all wards, thereby improving patient safety.

Objective To undertake an analysis of hospital pharmacy staffing levels in England comparing national and regional averages for 2007/2008 and 2012/2013. Methods Individual hospital pharmacy staffing establishment data were extracted from the National Health Service (NHS) Pharmacy Education and Development Committee's National NHS Pharmacy Staffing Establishment and Vacancy Survey for 2007/2008 and 2012/2013. Hospital activity data for the 2 years were extracted from the NHS Health and Social Care Information Centre website. For each hospital, the number of whole time equivalent (WTE) pharmacy staff was divided by the number of admissions and a percentage WTE/admission calculated. Acute hospitals were analysed separately from mental health hospitals. Results The mean % WTE pharmacy staff/admission in acute hospitals in England 2012/2013 was 0.114 compared with 0.112 in 2007/2008 (p>0.05). The means for individual staff groups have either remained unchanged or have reduced slightly. There were also changes by region with some increasing and others decreasing. The changes in mental health and social care trusts were more marked with the median % WTE pharmacy staff/admission almost doubling in 2012/2013 compared with 2007/2008. This increase in establishment was seen in all pharmacy staff groups. Conclusions The number of pharmacy staff per admission in acute hospitals in England between 2007/2008 and 2012/2013 has not changed significantly. This indicates that pharmacy services have kept pace with increasing activity. In contrast, pharmacy staffing levels in mental health trusts have almost doubled in the intervening 5 years as a result of a national initiative to develop the workforce in mental health services.